Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
- Mechanism
- Curator reviewed
Ramoplanin is the first in a new class of antimicrobials to reach clinical trials. It is a glycolipodepsipeptide produced by the fermentation of Actinoplanes spp.. Ramoplanin blocks bacterial cell wall biosynthesis by interfering with peptidoglycan production. Ramoplanin inhibits the N-acetylglucosaminyltransferase-catalysed conversion of lipid intermediate I to lipid intermediate II, a step that occurs before the transglycosylation and transpeptidation reactions. Ramoplanin’s mechanism of action is distinct from that of glycopeptides. Unlike glycopeptides, ramoplanin does not complex with the D-Ala–D-Ala sequence of cell wall precursors.
- Primary indication
- For the treatment of bacterial infections.Curator reviewed
Resolves to
What you can answer from here — as of August 31, 2026
Which drugs share a target with Ramoplanin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account